Jieer Ying

机构：Chinese Academy of Medical Sciences & Peking Union Medical College, Wenzhou Medical University, Zhejiang Cancer Hospital, Zhejiang Academy of Social Sciences, Blood Center of Zhejiang Province, Cancer Hospital of Chinese Academy of Medical Sciences, University of Chinese Academy of Sciences, Hangzhou Cancer Hospital · ORCID：0000-0001-9452-1242

发表论文 180 篇 · 总被引 8165 次 · h-index 30

代表论文

• First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial (2025 · Nature Medicine · 被引 89)
• DLAT activates EMT to promote HCC metastasis by regulating GLUT1-mediated aerobic glycolysis (2025 · Molecular Medicine · 被引 21)
• Perivascular Niche–Resident Alveolar Macrophages Promote Interstitial Pneumonitis Related to Trastuzumab Deruxtecan Treatment (2025 · Cancer Research · 被引 20)
• Sintilimab and anlotinib with gemcitabine plus cisplatin in advanced biliary tract cancer: SAGC a randomized phase 2 trial (2025 · Nature Communications · 被引 12)
• Claudin18.2 (CLDN18.2) expression and efficacy in pancreatic ductal adenocarcinoma (PDAC): Results from a phase I dose expansion cohort evaluating IBI343. (2025 · Journal of Clinical Oncology · 被引 10)
• First-Line Pembrolizumab Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-859 Study (2025 · Advances in Therapy · 被引 9)